HMGB1 mediates endogenous TLR2 activation and brain tumor regression
about
The implication and potential applications of high-mobility group box 1 protein in breast cancerCirculating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune DiseasesOverview of current immunotherapeutic strategies for gliomaRadio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical ApplicationsThe role of mesenchymal stem cells in cancer developmentGene therapy for brain tumors: basic developments and clinical implementationDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsAre BiTEs the "missing link" in cancer therapy?Toll-like receptor 4 enhancement of non-NMDA synaptic currents increases dentate excitability after brain injury.DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunityAlarmins: awaiting a clinical responseCombined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growthBlocking TLR2 activity attenuates pulmonary metastases of tumor.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regressionAssessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBMPreclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapyHuman Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.High-mobility group box 1 and cancer.Toll-like receptor 2 and facial motoneuron survival after facial nerve axotomy.Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo.Single vs. combination immunotherapeutic strategies for glioma.Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeuticsEffects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse modelMarmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathologyGene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathwayToll-like receptors and cancer, particularly oral squamous cell carcinoma.Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.Human herpesvirus 6 latent infection in patients with glioma.Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.HMGB1 in health and disease.
P2860
Q26744069-66A0FC1B-FC26-44D0-A9F7-5086A763E5B2Q26768480-86C1B7A4-8D90-434E-ABEB-11A2BB8196E4Q26776345-9E98B955-09F2-4DC2-94E2-1C5D786FD004Q26779221-D5E3C776-C064-4B36-8EA0-7341CA46A547Q26823870-50D17E92-FE8F-473A-A8CC-164BED5D4975Q26829086-6C18DE02-E4DD-4458-BD03-97E7273D837AQ27014829-0ABD3DFD-60AD-47A3-BCA5-EE460E85A28BQ28083907-B15AF6B4-1EEB-4666-A377-9D8E1872CA76Q30392483-98AE59F9-FDDB-462C-9111-28B785AF7726Q30499197-57BFE47C-9033-4DF7-A17E-628F00F57396Q30523797-0072245A-B9F5-4D20-ABA9-F15646477BBAQ30842176-483EB65A-F4F5-4656-82CD-4EBB7DC3A7CEQ33490618-ED25A1AC-0759-4916-AF11-AC7140EA4EE3Q33551268-245BFEF9-5931-4DDB-B89B-724C68FB268CQ33578030-2EF75A07-356F-4FEB-81A9-C4028B990EECQ33603599-95FDA56E-D16A-497C-9306-7B808C3F0AC2Q33605719-1BF7C655-E131-402A-8A76-9C6AA4DB7105Q33638306-0951F169-831A-4767-B1A2-8A996048ED89Q33673185-48FB1B23-1B33-46D6-88B9-880887E3C4A5Q33740759-EE5E175F-7FBD-43D4-8A4A-A4D1734641C3Q33746041-2C171C7C-E103-47DA-9850-147777167E6EQ33828102-C7EA4C42-E68A-4D23-AFDE-E3CEB8E7975AQ33828114-21025044-B11E-4FB8-A010-2F0C33376BA8Q33877450-655DCE4C-31DB-4813-BEF6-4AC4F3C54D41Q33908539-2A8EA589-C6D3-494E-A67B-E534205E5AABQ33924763-D98E5335-8D62-4711-8EBE-E8BE2DF5A38CQ33950709-96691D1A-72BB-41AA-B5F1-7CF270500401Q34000194-59F4268F-CB92-4551-9C7B-0F95F9C5A616Q34012284-AB55E68A-80C1-4BAF-9C4C-86EF3FF6F0A5Q34022048-BF3B0622-7927-4BDD-9389-0DB31BADA37CQ34069598-543E30CC-B610-4F8B-BF6D-5B88471BE8ACQ34116278-7B1F0BF2-F55B-4BCF-8801-C8EE0C38FD82Q34208293-022420E9-E99B-44DE-81A9-BE1B28B487FDQ34227734-61AC1F81-EA19-4374-814E-348B2899473BQ34239239-B095D94B-5A58-42DD-97EE-E401E12642CCQ34287535-7C740413-BF22-4B5D-BC3B-8F62B4E7A6F3Q34298606-428BF2CA-369A-4C09-BF9B-8D9D26774875Q34359268-038A39F4-907D-4214-9112-AC736EEAA1BCQ34486464-12EBD012-5CD0-4763-A9AC-A9A1029FCD90Q34622835-9FE698D7-172D-49E4-9481-418028A7598A
P2860
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@ast
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@en
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@nl
type
label
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@ast
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@en
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@nl
prefLabel
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@ast
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@en
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@nl
P2093
P2860
P3181
P1433
P1476
HMGB1 mediates endogenous TLR2 activation and brain tumor regression
@en
P2093
A K M Ghulam Muhammad
Begonya Comin-Anduix
Chunyan Liu
Hikmat Assi
James F Curtin
Kader Yagiz
Kathrin S Michelsen
Kurt M Kroeger
Maria G Castro
Marianela Candolfi
P2860
P3181
P356
10.1371/JOURNAL.PMED.1000010
P407
P577
2009-01-13T00:00:00Z